The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company’s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.

Supplemental cash flow information related to operating leases is as follows (dollars in thousands):

	Six Months Ended
	June 30, 2020
Cash payments for operating leases	$	1,765
Right-of-use assets obtained in exchange for operating lease obligations		265

	June 30, 2020
Weighted-average remaining lease term	8.8 years
Weighted-average discount rate		8.9	%

Future minimum non-cancelable payments under operating leases as of June 30, 2020, were as follows (in thousands):

	Operating Leases
2020 (remainder)	$	1,635
2021		3,460
2022		2,937
2023		2,793
2024		2,711
Thereafter		16,052
Total future lease payments		29,588
Less imputed interest		10,184
Present value of lease liabilities	$	19,404

The operating lease expense for the three and six months ended June 30, 2020 and 2019, were as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
(in thousands)	2020		2019		2020		2019
Operating lease expense	$	839	$	912	$	1,663	$	1,458

The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.